The Criteria for the clinical use of immunoglobulin in Australia (the Criteria) undergoes periodic review to reflect the latest scientific evidence and expert advice from our National Immunoglobulin Governance Advisory Committee and its Specialist Working Groups.
This page summarises the changes to the Criteria which were implemented in 2023. Changes are applied immediately to new authorisations and to existing authorisations at the next continuing treatment request, unless otherwise stated. For more information about any of these changes, please contact the Ig Governance team at IgGovernance@blood.gov.au.
November 2023
Autoimmune encephalitis mediated by antibodies targeting cell-surface antigens (AMAE) – Version 3.2
- Dosing frequency has been updated to allow greater flexibility.
- Other minor typographical changes.
Chronic inflammatory demyelinating polyneuropathy (CIDP), (including IgG and IgA paraproteinaemic demyelinating neuropathies) – Version 3.3
- Minor typographical changes.
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) – Version 3.1
- Minor typographical changes.
Immune thrombocytopenic purpura (ITP) – adult – Version 3.2
- Minor typographical changes.
Immune thrombocytopenic purpura (ITP) - in children 15 years and younger – Version 3.2
- Minor typographical changes.
Multifocal motor neuropathy (MMN) – Version 3.1
- Minor typographical changes.
Myasthenia gravis (MG) – Version 3.1
- Minor typographical changes.
Paediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS) or paediatric acute neuropsychiatric disorders (PANS) – Version 3.2
- Minor typographical changes.
Post-transfusion purpura (PTP) – Version 3.1
- Minor typographical changes.
Primary immunodeficiency diseases (PID) with antibody deficiency – Version 3.4
- Lowered the qualifying age to 2 years (from 4 years) for indication 1.
Rasmussen encephalitis – Version 3.1
- Minor typographical changes.
Secondary hypogammaglobulinaemia unrelated to haematological malignancy or haemopoietic stem cell transplant (HSCT) – Version 3.4
- A higher maintenance dose is now permitted for chronic disseminated enterovirus infection.
- Other minor typographical changes.
Sjögren’s syndrome associated neuropathy – Version 3.1
- Minor typographical changes.
Stiff person syndrome – Version 3.1
- Minor typographical changes.
Susac syndrome – Version 3.2
- Minor typographical changes.
Vaccine induced immune thrombotic thrombocytopenia (VITT)/ Vaccine induced prothrombotic immune thrombocytopenia (VIPIT) – Version 3.0
- Temporary status removed.
March 2023
Solid organ transplantation – Version 3.1
- The biopsy evidence item has been made non-mandatory for indication 3.
- Dosing controls for all indications have been updated to allow greater flexibility in frequency of dosing.
- Maximum dose for indication increased from 0.5 g/kg to 1.0 g/kg.
- Other minor typographical changes.
Last updated: 03 Feb 2026